Analysts Lift OrthoPediatrics and Pulmonx Price Targets to $29 and $3.7
Average 12-month targets rose to $29 for OrthoPediatrics and $3.7 for Pulmonx, per FactSet data cited by TradingView, with consensus still Buy.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, citing FactSet, eight analysts raised the average 12-month price target for OrthoPediatrics Corp. stock from $27.5 to $29. Forecasts range from $23 to $35. Based on the October 27 close, the updated target implies about 22% potential upside. The consensus rating remains Buy, with seven Buy ratings, one Hold and no Sells.
Separately, five analysts lifted the average 12-month price target for Pulmonx Corporation stock from $3.4 to $3.7, with forecasts from $2.5 to $5. Against the same closing price, the target implies roughly 87% upside. The consensus is also Buy, with three Buys, two Holds and no Sells.
why it matters
Price target revisions for individual stocks are routine and mainly reflect analysts' views rather than broad market moves. The news matters most to shareholders and followers of these two companies.
tags
instruments
sources
- OrthoPediatrics Corp. Stock 12‑Month Price Target Raised to $29, Implies 22% Upside — TradingView, 28 October 2026 at 07:20 UTC
- Pulmonx Corporation Stock 12‑Month Price Target Raised to $3.7, Implies 87% Upside — TradingView, 28 October 2026 at 07:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗